
Between rapidly shifting tariffs, freezes to federal grant funding and changing U.S. Food and Drug Administration policies, R.I. Bio Director Glenn Robertelli acknowledges that 2025 was a turbulent year for the life sciences. But at the local level, Robertelli says, the sector has managed to ride out the storm. “Here in Rhode Island, despite the
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber













